Order Article Reprints

Alherz FA, El-Masry TA, Oriquat GA, Elekhnawy E, Al-Shaalan NH, Gaballa MMS, El Zahaby EI, El-Nagar MMF. Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade. Pharmaceuticals. 2024; 17(9):1144. https://doi.org/10.3390/ph17091144

Alherz, Fatemah A., Thanaa A. El-Masry, Ghaleb A. Oriquat, Engy Elekhnawy, Nora Hamad Al-Shaalan, Mohamed M. S. Gaballa, Enas I. El Zahaby, and Maysa M. F. El-Nagar. 2024. "Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade" Pharmaceuticals 17, no. 9: 1144. https://doi.org/10.3390/ph17091144

Alherz, F. A., El-Masry, T. A., Oriquat, G. A., Elekhnawy, E., Al-Shaalan, N. H., Gaballa, M. M. S., El Zahaby, E. I., & El-Nagar, M. M. F. (2024). Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade. Pharmaceuticals, 17(9), 1144. https://doi.org/10.3390/ph17091144